INCY News and Press, Incyte Corporation From 03/07/23

2023-03-07 07:03:02 ET Caris Life Sciences (Caris) announces a strategic research partnership with Incyte ( NASDAQ: INCY ) to augment precision medicine approaches for Incyte's oncology pipeline. The partnership will apply Caris' data and analytics tools, comprehe...

Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology Pipeline PR Newswire IRVING, Texas , March 7, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading molecular science and technology...

Three late-breaking presentations in vitiligo highlight new long-term data from the Phase 3 TRuE-V trials for Opzelura ® (ruxolitinib) cream and results from a Phase 2b study with povorcitinib (INCB54707), an oral JAK1 inhibitor Incyte to host an in-person analyst and investor ev...

Incyte ( NASDAQ: INCY ) said it would end a phase 3 program examining its myelofibrosis candidate parsaclisib with Jakafi (ruxolitinib) after an interim analysis showed the study was unlikely to meet its primary endpoint. The primary endpoint of the LIMBER-304 study was the ratio of p...

Independent data monitoring committee advises study unlikely to meet primary endpoint, leading to decision to discontinue the study Incyte (Nasdaq:INCY) today announced that it will discontinue the Phase 3 LIMBER-304 trial following results of a pre-planned interim analysis conducted ...

Summary Syndax Pharmaceuticals, Inc. has two pivotal trials with data readouts coming up in 2023, with possible regulatory filings. They are loaded with cash after a successful offering. Despite current highs, I see further upside in 2023. Syndax Pharmaceuticals, Inc. ( ...

Incyte ( NASDAQ: INCY ) announced Friday that a group of medical experts in the EU recommended the marketing authorization of ruxolitinib cream for non-segmental vitiligo with facial involvement in those aged 12 years and above. The decision of the European Medicines Agency’s (...

At approval, ruxolitinib cream will be the first treatment for repigmentation in non-segmental vitiligo available in the European Union (EU) In Europe, there are approximately 1.5 million patients diagnosed with vitiligo, a progressive and complex disease with a high unmet need Th...

Incyte ( NASDAQ: INCY ) said an extension period of a phase 2 trial showed that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy in patients with a type of skin condition called Hidradenitis suppurativa (HS). The company reported new 52-wee...

- Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms - Data featured as an oral presentation at the European Hidradenitis Suppurativa Foundation...